

Paper No. _____
Filed: July 30, 2019

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC,
Petitioner

v.

ALKERMES PHARMA IRELAND LIMITED,
Patent Owner

Case IPR2018-00943
Patent 7,919,499

**JOINT REQUEST TO TREAT SETTLEMENT AND
LICENSE AGREEMENT AS BUSINESS CONFIDENTIAL
PURSUANT TO 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74(c)**

Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), Patent Owner Alkermes Pharma Ireland Limited and Petitioner Amneal Pharmaceuticals LLC (collectively, “the Parties”) jointly request that a true copy of the Settlement and License Agreement filed concurrently herewith as Exhibit 2058 be treated as “business confidential” and be kept separate from the publicly available files of the above-captioned IPR and of the ’499 patent. Exhibit 2058 is being submitted on the PTAB E2E system as “Parties and Board Only.” The Parties further request the Board to not make Exhibit 2058 available to any third party, except as provided for in 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).

Respectfully submitted,

Dated: July 30, 2019

By: /Tedd W. Van Bustkirk/
Tedd W. Van Buskirk (Reg. No. 46,282)
Counsel for Petitioner
Amneal Pharmaceuticals LLC

By: /Naveen Modi/
Naveen Modi (Reg. No. 46,224)
Counsel for Patent Owner
Alkermes Pharma Ireland Limited

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served on the counsel for Petitioner a true and correct copy of the foregoing JOINT REQUEST TO TREAT SETTLEMENT AND LICENSE AGREEMENT AS BUSINESS CONFIDENTIAL, by electronic means, on July 30, 2019, at the following address of record:

Michael H. Teschner
Tedd W. Van Buskirk
Lerner, David, Littenberg,
Krumholz & Mentlik, LLP
600 South Avenue West
Westfield, NJ 07090

MTeschner.ipr@ldlkm.com
tvanbuskirk@lernerdavid.com
litigation@lernerdavid.com

Dated: July 30, 2019

Respectfully submitted,

By: /Naveen Modi/
Naveen Modi
Reg. No. 46,224

Counsel for Alkermes